<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084029</url>
  </required_header>
  <id_info>
    <org_study_id>UESTC-neuSCAN-03</org_study_id>
    <nct_id>NCT03084029</nct_id>
  </id_info>
  <brief_title>The Neural Basis of Oxytocin's Effects on Empathy</brief_title>
  <official_title>The Neural Basis of Oxytocin's Effects on Empathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Electronic Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Electronic Science and Technology of China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main focus of this study is to examine oxytocin effects on behavioral and neural indices
      of empathy processing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The neuropeptide oxytocin (OXT) has been demonstrated to modulate empathy in previous
      behavioural studies. The present study aims at replicating previous findings on OXT on
      empathy as well as to determine the neural basis of these effects.

      In a between-subject, randomized double-blind design, subjects will be either administered
      intranasal OXT or placebo nasal spray (40 IU). 45 minutes after administration subjects will
      undergo (fMRI) tasks of empathic processing.

      During the tasks subjects will be shown empathy inducing stimuli, and the behavioral and
      neural response in terms of cognitive, emotional and indirect emotional empathy will be
      assessed.

      Before the administration of treatment, validated questionnaires assessing potential
      confounding variables, such as depression (Becks Depression Inventory (BDI)) or mood
      (Positive And Negative Affect Scale (PANAS)) will be administered to the subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neural processing of empathy as assessed using fMRI</measure>
    <time_frame>45-115 minutes after single dose administration</time_frame>
    <description>Main effects of treatment and interaction between treatment effects and sex will be assessed on brain activity and connectivity in core regions of the empathy networks during processing of empathy inducing pictures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behavioral ratings of subjective experienced empathy processing</measure>
    <time_frame>45-115 minutes after single dose administration</time_frame>
    <description>Main effects of treatment and interaction between treatment effects and sex will be assessed on subjective feelings of empathy (ratings on a Likert scale in response to empathy inducing pictures).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>male participants - oxytocin nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>male participants - receiving a single dose of 40 IU intranasal oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>female participants - oxytocin nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>female participants - receiving a single dose of 40 IU intranasal oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>male participants - placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>male participants - receiving a single dose of 40 IU intranasal placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>female participants - placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>female participants - receiving a single dose of 40 IU intranasal placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>40 international units</description>
    <arm_group_label>male participants - oxytocin nasal spray</arm_group_label>
    <arm_group_label>female participants - oxytocin nasal spray</arm_group_label>
    <other_name>Oxytocin Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>40 international units</description>
    <arm_group_label>male participants - placebo nasal spray</arm_group_label>
    <arm_group_label>female participants - placebo nasal spray</arm_group_label>
    <other_name>Placebo treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects without past or current psychiatric or neurological disorders

          -  no smoking at least 12 hours before experiment

          -  no alcohol, coffee or other stimulant drinking at least 12 hours before experiment

        Exclusion Criteria:

          -  mental implants

          -  pregnancy

          -  uterine cavity operations

          -  use of medication

          -  acute physical disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Kendrick, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China,Sichuan, School of Life Science and Technology,University of Electronic Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>School of Life Science and Technology,University of Electronic Science and Technology</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <last_update_submitted>February 4, 2018</last_update_submitted>
  <last_update_submitted_qc>February 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Electronic Science and Technology of China</investigator_affiliation>
    <investigator_full_name>Keith Kendrick</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>fMRI</keyword>
  <keyword>empathy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

